Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-12

Clinical Trial Update: Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months

View source ↗

Summary

A completed clinical trial assessing the effects of Aubagio (teriflunomide) on brain pathology in people with multiple sclerosis over 12 months.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AUBAGIO (TERIFLUNOMIDE)

Snippet

Sponsor: University at Buffalo | Conditions: Multiple Sclerosis | Status: COMPLETED